Brown A, et al. - Authors performed the phase 2 C-SCAPE study to evaluate elbasvir/grazoprevir (EBR/GZR), with or without ribavirin (RBV), in participants with hepatitis C virus (HCV) genotype 2, 4, 5 or 6 infection. As per findings, the inclusion of participants with genotype 4 or 6 infection in the EBR/GZR phase 3 studies was supported. For participants with genotype 2 or 5 infection, EBR/GZR±RBV seemed unsatisfactory.